Endocrinology and Metabolism

Original Articles

Thyroid
Diagnostic Accuracy of Preoperative Radiologic Findings in Papillary Thyroid Microcarcinoma: Discrepancies with the Postoperative Pathologic Diagnosis and Implications for Clinical Outcomes: Ying Li, Seul Ki Kwon, Hoonsung Choi, Yoo Hyung Kim, Sunyoung Kang, Kyeong Cheon Jung, Jae-Kyung Won, Do Joon Park, Young Joo Park, Sun Wook Cho; Endocrinol Metab. 2024;39(3):450-460. Published online May 27, 2024; DOI: https://doi.org/10.3803/EnM.2023.1872

1,510 View
57 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The diagnostic accuracy of preoperative radiologic findings in predicting the tumor characteristics and clinical outcomes of papillary thyroid microcarcinoma (PTMC) was evaluated across all risk groups.
Methods
In total, 939 PTMC patients, comprising both low-risk and non-low-risk groups, who underwent surgery were enrolled. The preoperative tumor size and lymph node metastasis (LNM) were evaluated by ultrasonography within 6 months before surgery and compared with the postoperative pathologic findings. Discrepancies between the preoperative and postoperative tumor sizes were analyzed, and clinical outcomes were assessed.
Results
The agreement rate between radiological and pathological tumor size was approximately 60%. Significant discrepancies were noted, including an increase in tumor size in 24.3% of cases. Notably, in 10.8% of patients, the postoperative tumor size exceeded 1 cm, despite being initially classified as 0.5 to 1.0 cm based on preoperative imaging. A postoperative tumor size >1 cm was associated with aggressive pathologic factors such as multiplicity, microscopic extrathyroidal extension, and LNM, as well as a higher risk of distant metastasis. In 30.1% of patients, LNM was diagnosed after surgery despite not being suspected before the procedure. This group was characterized by smaller metastatic foci and lower risks of distant metastasis or recurrence than patients with LNM detected both before and after surgery.
Conclusion
Among all risk groups of PTMCs, a subset showed an increase in tumor size, reaching 1 cm after surgery. These cases require special consideration due to their association with adverse clinical outcomes, including an elevated risk of distant metastasis.

Thyroid
Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Jinsun Lim, Han Sai Lee, Jin-Hyung Heo, Young Shin Song; Endocrinol Metab. 2024;39(2):324-333. Published online April 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1885

1,870 View
56 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The predictive factors for lateral neck lymph node metastasis (LLNM) in papillary thyroid microcarcinoma (PTMC) remain undetermined. This study investigated the clinicopathological characteristics, transcriptomes, and tumor microenvironment in PTMC according to the LLNM status. We aimed to identify the biomarkers associated with LLNM development.
Methods
We retrospectively reviewed the medical records of patients with PTMC from two independent institutions between 2018 and 2022 (n=597 and n=467). We compared clinicopathological features between patients without lymph node metastasis (N0) and those with LLNM (N1b). Additionally, laser capture microdissection and RNA sequencing were performed on primary tumors from both groups, including metastatic lymph nodes from the N1b group (n=30; 20 primary tumors and 10 paired LLNMs). We corroborated the findings using RNA sequencing data from 16 BRAF-like PTMCs from The Cancer Genome Atlas. Transcriptomic analyses were validated by immunohistochemical staining.
Results
Clinicopathological characteristics, such as male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis showed associations with LLNM in PTMCs. Transcriptomic profiles between the N0 and N1b PTMC groups were similar. However, tumor microenvironment deconvolution from RNA sequencing and immunohistochemistry revealed an increased abundance of tumor-associated macrophages, particularly M2 macrophages, in the N1b group.
Conclusion
Patients with PTMC who have a male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis exhibited an elevated risk for LLNM. Furthermore, infiltration of M2 macrophages in the tumor microenvironment potentially supports tumor progression and LLNM in PTMCs.

Thyroid
Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis: Mijin Kim, Chae Hwa Kwon, Min Hee Jang, Jeong Mi Kim, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, Kyung-Un Choi, In Joo Kim, Meeyoung Park, Bo Hyun Kim; Endocrinol Metab. 2021;36(5):1086-1094. Published online October 28, 2021; DOI: https://doi.org/10.3803/EnM.2021.1132

4,284 View
115 Download
5 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Early identification of patients with high-risk papillary thyroid microcarcinoma (PTMC) that is likely to progress has become a critical challenge. We aimed to identify somatic mutations associated with lateral neck lymph node (LN) metastasis (N1b) in patients with PTMC.
Methods
Whole-exome sequencing (WES) of 14 PTMCs with no LN metastasis (N0) and 13 N1b PTMCs was performed using primary tumors and matched normal thyroid tissues.
Results
The mutational burden was comparable in N0 and N1b tumors, as the median number of mutations was 23 (range, 12 to 46) in N0 and 24 (range, 12 to 50) in N1b PTMC (P=0.918). The most frequent mutations were detected in PGS1, SLC4A8, DAAM2, and HELZ in N1b PTMCs alone, and the K158Q mutation in PGS1 (four patients, Fisher’s exact test P=0.041) was significantly enriched in N1b PTMCs. Based on pathway analysis, somatic mutations belonging to the receptor tyrosine kinase-RAS and NOTCH pathways were most frequently affected in N1b PTMCs. We identified four mutations that are predicted to be pathogenic in four genes based on Clinvar and Combined Annotation-Dependent Depletion score: BRAF, USH2A, CFTR, and PHIP. A missense mutation in CFTR and a nonsense mutation in PHIP were detected in N1b PTMCs only, although in one case each. BRAF mutation was detected in both N0 and N1b PTMCs.
Conclusion
This first comprehensive WES analysis of the mutational landscape of N0 and N1b PTMCs identified pathogenic genes that affect biological functions associated with the aggressive phenotype of PTMC.

Citations

Citations to this article as recorded by

What can we learn about acid-base transporters in cancer from studying somatic mutations in their genes?
Bobby White, Pawel Swietach
Pflügers Archiv - European Journal of Physiology.2024; 476(4): 673. CrossRef
Comprehensive Long-Read Sequencing Analysis Discloses the Transcriptome Features of Papillary Thyroid Microcarcinoma
Yanqiang Wang, Binbin Zou, Yanyan Zhang, Jin Zhang, Shujing Li, Bo Yu, Zhekun An, Lei Li, Siqian Cui, Yutong Zhang, Jiali Yao, Xiuzhi Shi, Jing Liu
The Journal of Clinical Endocrinology & Metabolism.2024; 109(5): 1263. CrossRef
Feasibility of whole‐exome sequencing in fine‐needle aspiration specimens of papillary thyroid microcarcinoma for the identification of novel gene mutations
Liyuan Ma, Luying Gao, Ya Hu, Xiaoyi Li, Chunhao Liu, Jiang Ji, Xinlong Shi, Aonan Pan, Yuang An, Nengwen Luo, Yu Xia, Yuxin Jiang
Clinical Genetics.2024; 105(5): 567. CrossRef
Multi-omics analysis reveals a molecular landscape of the early recurrence and early metastasis in pan-cancer
Dan-ni He, Na Wang, Xiao-Ling Wen, Xu-Hua Li, Yu Guo, Shu-heng Fu, Fei-fan Xiong, Zhe-yu Wu, Xu Zhu, Xiao-ling Gao, Zhen-zhen Wang, Hong-jiu Wang
Frontiers in Genetics.2023;[Epub] CrossRef

Thyroid
Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway: Jun-Qing Jin, Jeong-Sun Han, Jeonghoon Ha, Han-Sang Baek, Dong-Jun Lim; Endocrinol Metab. 2021;36(5):1095-1110. Published online October 14, 2021; DOI: https://doi.org/10.3803/EnM.2021.1155

5,468 View
173 Download
11 Web of Science
9 Crossref

Abstract PDF PubReader ePub

Background
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands have been widely shown to correlate with epithelial-mesenchymal transition (EMT) and cancer progression. Lobeglitazone (LGZ) is a novel ligand of PPAR-γ; and its role in EMT and metastasis in papillary thyroid carcinoma (PTC) is poorly understood. We aimed to investigate the role of LGZ in metastatic behavior of PTC cells.
Methods
Half maximal inhibitory concentration (IC₅₀) values of LGZ in BRAF-mutated PTC cell lines (BCPAP and K1) were determined using MTT assay. Rosiglitazone (RGZ), the PPAR-γ ligand was used as a positive control. The protein expression of PPAR-γ, cell-surface proteins (E-cadherin, N-cadherin), cytoskeletal protein (Vimentin), transcription factor (Snail), p38 mitogenactivated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2 pathway, and matrix metalloproteinase (MMP)-2 expression were measured using Western blotting. Changes in E-cadherin expression were also determined using immunocytochemistry. Cell migration and invasion were analyzed using wound healing and Matrigel invasion assays.
Results
Treatment with LGZ or RGZ significantly inhibited transforming growth factor-beta1 (TGF-β1)-induced EMT-associated processes such as fibroblast-like morphological changes, EMT-related protein expression, and increased cell migration and invasion in BCPAP and K1 cells. LGZ restored TGF-β1-induced loss of E-cadherin, as observed using immunocytochemistry. Furthermore, LGZ and RGZ suppressed TGF-β1-induced MMP-2 expression and phosphorylation of p38 MAPK, but not ERK1/2. Although there was no change in PPAR-γ expression after treatment with LGZ or RGZ, the effect of downstream processes mediated by LGZ was hampered by GW9662, a PPAR-γ antagonist.
Conclusion
LGZ inhibits TGF-β1-induced EMT, migration, and invasion through the p38 MAPK signaling pathway in a PPAR-γ-dependent manner in PTC cells.

Citations

Citations to this article as recorded by

Associations between Diabetes Mellitus and Selected Cancers
Monika Pliszka, Leszek Szablewski
International Journal of Molecular Sciences.2024; 25(13): 7476. CrossRef
Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention
Rongqian Wu, Junping Zhang, Guilin Zou, Shanshan Li, Jinying Wang, Xiaoxinlei Li, Jixiong Xu
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 809. CrossRef
Clinicopathological Evaluation of Papillary Thyroid Microcarcinoma
Ando Takahito, Kimihito Fujii, Hirona Banno, Masayuki Saito, Yukie Ito, Mirai Ido, Manami Goto, Yukako Mouri, Junko Kousaka, Tsuneo Imai, Shogo Nakano
Cureus.2024;[Epub] CrossRef
Pioglitazone, a peroxisome proliferator‑activated receptor γ agonist, induces cell death and inhibits the proliferation of hypoxic HepG2 cells by promoting excessive production of reactive oxygen species
Guohao Huang, Mengfan Zhang, Manzhou Wang, Wenze Xu, Xuhua Duan, Xinwei Han, Jianzhuang Ren
Oncology Letters.2024;[Epub] CrossRef
The Activation of PPARγ by (2Z,4E,6E)-2-methoxyocta-2,4,6-trienoic Acid Counteracts the Epithelial–Mesenchymal Transition Process in Skin Carcinogenesis
Enrica Flori, Sarah Mosca, Giorgia Cardinali, Stefania Briganti, Monica Ottaviani, Daniela Kovacs, Isabella Manni, Mauro Truglio, Arianna Mastrofrancesco, Marco Zaccarini, Carlo Cota, Giulia Piaggio, Mauro Picardo
Cells.2023; 12(7): 1007. CrossRef
Cumulative exposure to metabolic syndrome increases thyroid cancer risk in young adults: a population-based cohort study
Jinyoung Kim, Kyungdo Han, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
The Korean Journal of Internal Medicine.2023; 38(4): 526. CrossRef
Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
Alessia Greco, Francesca Coperchini, Laura Croce, Flavia Magri, Marsida Teliti, Mario Rotondi
Frontiers in Pharmacology.2023;[Epub] CrossRef
Fish and the Thyroid: A Janus Bifrons Relationship Caused by Pollutants and the Omega-3 Polyunsaturated Fatty Acids
Salvatore Benvenga, Fausto Famà, Laura Giovanna Perdichizzi, Alessandro Antonelli, Gabriela Brenta, Francesco Vermiglio, Mariacarla Moleti
Frontiers in Endocrinology.2022;[Epub] CrossRef
Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review
Gabriella Guo Sciriha, Janet Sultana, Joseph Borg
Expert Review of Clinical Pharmacology.2022; 15(12): 1423. CrossRef

Clinical Study
Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy: Meihua Jin, Jonghwa Ahn, Yu-Mi Lee, Tae-Yon Sung, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon; Endocrinol Metab. 2020;35(3):602-609. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.741

5,992 View
125 Download
2 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Background
The optimal dose of radioactive iodine (RAI) therapy for N1b papillary thyroid carcinoma (PTC) is controversial. We evaluated the clinical outcome of N1b PTC patients treated with either 100 or 150 mCi of RAI.
Methods
We retrospectively analyzed N1b PTC patients who underwent total thyroidectomy and postoperative RAI therapy at a tertiary referral center between 2012 and 2017. As the baseline characteristics differed between treatment groups, we performed exact matching for various pathological factors according to RAI dose. We evaluated the response to therapy and recurrence-free survival (RFS) in the matched patients. Structural recurrent/persistent disease was defined as new structural disease detected after initial therapy, which was confirmed by cytology or pathology.
Results
Of the total 436 patients, 37 (8.5%) received 100 mCi of RAI and 399 (91.5%) received 150 mCi of RAI. After an exact 1:3 matching, 34 patients in the 100 mCi group and 100 patients in the 150 mCi group remained. There was no significant difference in response to therapy between the groups in the matched population (P=0.63). An excellent response was achieved in 70.6% (n=24) of patients in the 100 mCi group and 76.0% (n=76) in the 150 mCi group. Two (5.9%) patients in the 100 mCi group and four (4.0%) in the 150 mCi group had recurrence and there was no significant difference in RFS between the groups in the matched population (P=0.351).
Conclusion
There were no differences in response to therapy and RFS in N1b PTC patients according to RAI dose.

Citations

Citations to this article as recorded by

Controversies in the Management of Intermediate-Risk Differentiated Thyroid Cancer
David Toro-Tobon, Juan P. Brito
Endocrine Practice.2024; 30(9): 879. CrossRef

Clinical Study
Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment: Oksana Sulaieva, Olena Chernenko, Oleksiy Selesnov, Oleksandr Nechay, Oleksandr Maievskyi, Tetyana Falalyeyeva, Nazarii Kobyliak, Olena Tsyryuk, Yurii Penchuk, Dmytro Shapochka; Endocrinol Metab. 2020;35(2):443-455. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.443

7,276 View
175 Download
13 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The relationship between Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) remains uncertain. We assessed the impact of HT on the tumor immune microenvironment (TIME) in PTC.
Methods
Thirty patients with PTC (group 1) and 30 patients with PTC and HT (group 2) were enrolled in this pilot study. The distribution and number of CD8+ lymphocytes, plasma cells (CD138+), regulatory T cells (forkhead box P3 [FOXP3+)], mast cell tryptase (MCT+), and M2 macrophages (CD163+) were evaluated. To test the hypothesis that HT impacts PTC development via signal transducer and activator of transcription 6 (STAT6) activation and M2 macrophage polarization, we investigated STAT6 expression in tumor and stromal cells. We also evaluated vascular endothelial growth factor (VEGF) expression by lymph node metastasis (LNM) status.
Results
TIME showed significant between-group differences. Group 1 patients demonstrated immune desert or immune-excluded immunophenotypes, while an inflamed phenotype with more CD8+ cells (P<0.001) predominated in group 2. Immune-excluded TIME was associated with the highest LNM rate. In PTC, LNM was associated with more numerous CD163+ cells. Moreover, LNM in group 1 was associated with increased numbers of mast cells peritumorally and FOXP3+ cells intratumorally and peritumorally. Group 2 demonstrated higher STAT6 but not higher VEGF expression in tumor cells. High VEGF expression was associated with LNM regardless of HT status.
Conclusion
Concomitant HT impacted PTC signaling via STAT6 and TIME by increasing the number of CD8+ cells. LNM is associated with increases in CD163+ cells and VEGF expression in PTC, whereas HT affected LNM through different mechanisms.

Citations

Citations to this article as recorded by

The impact of Hashimoto’s thyroiditis on the clinical outcome of papillary thyroid cancer after radioactive iodine therapy: a propensity score matching study
Jingjia Cao, Yaru Sun, Yang Liu, Yunfei Xu, Xiao Li, Wei Zhang, Ximing Wang
Endocrine.2024;[Epub] CrossRef
Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
Pathology - Research and Practice.2023; 245: 154431. CrossRef
Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance
Peter P. Issa, Ruhul Munshi, Aaron L. Albuck, Mahmoud Omar, Ruba F. Abu Alhuda, Tyler Metz, Mohammad Hussein, Mohamed Shama, Grace S. Lee, Eman Toraih, Emad Kandil
American Journal of Otolaryngology.2023; 44(6): 103994. CrossRef
Hashimoto's thyroiditis is negatively associated with lymph node metastasis in PTMC
Hui Huang, Siyuan Xu, Song Ni, Wensheng Liu, Shaoyan Liu
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15525. CrossRef
A nomogram based on the risk factors of cervical lymph node metastasis in papillary thyroid carcinoma coexistent with Hashimoto’s thyroiditis
Huanhuan Miao, Jingwen Zhong, Xuesha Xing, Jiawei Sun, Jiaqi Wu, Chengwei Wu, Yan Yuan, Xianli Zhou, Hongbo Wang
Clinical Hemorheology and Microcirculation.2023; 85(3): 235. CrossRef
The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
Nese E. GULCELIK, Safak AKIN, Kadriye AYDIN, Cisel AYDIN MERICOZ, Yesim G. GULER TEZEL, Aydan USMAN
Minerva Endocrinology.2023;[Epub] CrossRef
Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer
Meiye Li, Jimei Zhang, Zongjing Zhang, Ying Qian, Wei Qu, Zhaoshun Jiang, Baochang Zhao
Frontiers in Endocrinology.2022;[Epub] CrossRef
A Potential Nine-lncRNAs Signature Identification and Nomogram Diagnostic Model Establishment for Papillary Thyroid Cancer
Jin-Ming Yao, Jun-Yu Zhao, Fang-Fang Lv, Xue-Bo Yang, Huan-Jun Wang
Pathology and Oncology Research.2022;[Epub] CrossRef
Hyperhomocysteinemia in the pathogenesis of cardiovascular and endocrine diseases: translational messages
Rostyslav KAMINSKY, Andrii YANCHYSHYN, Natalia BELEMETS, Olena KURYK, Inga SAMBORSKA, Iryna DZEVULSKA, Rinaldo PELLICANO
Minerva Biotechnology and Biomolecular Research.2022;[Epub] CrossRef
Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
Oleksandr Stakhovskyi, Nazarii Kobyliak, Oleg Voylenko, Eduard Stakhovskyi, Roman Ponomarchuk, Oksana Sulaieva
Cells.2022; 11(11): 1802. CrossRef
Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
Yuepeng Zhang, Yueli Tian
BMC Endocrine Disorders.2022;[Epub] CrossRef
Research Progress in the Correlation between AID, BRAFV600E and Papillary Thyroid Carcinoma
鑫焦
Advances in Clinical Medicine.2022; 12(12): 11503. CrossRef
STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology
Georgia Karpathiou, Alexandra Papoudou-Bai, Elise Ferrand, Jean Marc Dumollard, Michel Peoc’h
Pathology - Research and Practice.2021; 223: 153477. CrossRef
Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
JAMA Network Open.2021; 4(7): e2118526. CrossRef
LARINGOPHARINGEAL REFLUX IMPACTS IMMUNE MICROENVIRONMENT OF LARYNGEAL CARCINOMA
D.I. Zabolotnyi, V.V. Kizim, D.D. Zabolotna, Y.V. Kizim, O.N. Sulaieva
Fiziolohichnyĭ zhurnal.2020; 66(4): 12. CrossRef

Thyroid
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age: Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2018;33(4):459-465. Published online November 30, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.4.459

5,353 View
59 Download
6 Web of Science
5 Crossref

Abstract PDF PubReader ePub

Background

Differentiated thyroid carcinoma (DTC) shows a very good prognosis, but older patients have a higher recurrence rate and those show poor prognosis than younger patients. The aim of this study was to determine the clinical outcomes of thyroid cancer patients who experienced recurrence in old age according to the treatment strategy used.

Methods

This retrospective observational cohort study was conducted at Asan Medical Center, Seoul, Korea. Among DTC patients with no evidence of disease after initial treatment, we enrolled 86 patients who experienced recurrence at an age >65 years from 1994 to 2012. Sixty-nine patients had local recurrence and 17 patients showed distant metastasis.

Results

The mean age of patients at recurrence was 72 years. Patients were followed up for a median of 4.1 years after recurrence. Sixty-three of the 69 patients with local recurrence received additional treatment, while the other six received conservative care. The cancer-specific mortality rate was 15.5% in the local recurrence group. Airway problems were the main cause of death in patients who did not receive further treatment for local recurrence. Among the 17 patients with distant metastasis, 10 underwent specific treatment for metastasis and seven received only supportive management. Seven of those 17 patients died, and the cancer-specific mortality rate was 35% in the distant metastasis group.

Conclusion

The overall cancer-specific mortality rate was 20% in DTC patients in whom recurrence was first detected at an age >65 years. Mortality due to uncontrolled local disease occurred frequently in patients who did not receive definitive management for recurrence.

Citations

Citations to this article as recorded by

125I seed implantation for lymph node metastasis from radioactive iodine-refractory differentiated thyroid carcinoma: a study on short-term efficacy and dosimetry
Wenwen Zhang, Shanhu Hao, Zhiguo Wang, Tingting Ding, Guoxu Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Identification of Circulating Tumor Cell Phenotype in Differentiated Thyroid Carcinoma
Huiling Wang, Mian Lv, Yonghong Huang, Xiaoming Pan, Changyuan Wei
Journal of Biomaterials and Tissue Engineering.2022; 12(4): 813. CrossRef
Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
Zhong-Ling Qiu, Chen-Tian Shen, Zhen-Kui Sun, Hong-Jun Song, Chuang Xi, Guo-Qiang Zhang, Yang Wang, Quan-Yong Luo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment
Yangmeihui Song, Fang Liu, Weiwei Ruan, Fan Hu, Muhsin H. Younis, Zairong Gao, Jie Ming, Tao Huang, Weibo Cai, Xiaoli Lan
Cancers.2021; 13(14): 3436. CrossRef
Highly sensitive electrochemical immunosensor using a protein-polyvinylidene fluoride nanocomposite for human thyroglobulin
Maria Oneide Silva de Moraes, João de Deus Pereira de Moraes Segundo, Marcos Marques da Silva Paula, Maria Goreti Ferreira Sales, Walter Ricardo Brito
Bioelectrochemistry.2021; 142: 107888. CrossRef

Thyroid
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea: Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung; Endocrinol Metab. 2018;33(2):287-295. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.287

6,202 View
70 Download
32 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Background

Most patients with differentiated thyroid cancer (DTC) have a favorable prognosis. However, patients with DTC and initial distant metastasis have not been commonly found, and their clinical characteristics have seldom been reported. In this study, we analyzed the clinical features and prognosis of patients with DTC and initial distant metastasis in Korea.

Methods

We retrospectively reviewed the clinical data of 242 patients with DTC and initial distant metastasis treated from 1994 to 2013, collected from five tertiary hospitals in Korea.

Results

The patients' median age was 51 years, and 65% were women. They were followed for a median of 7 years. Lung was the most common site of distant metastasis: only lung 149 patients (62%), only bone 49 (20%), other single site one (pleura), and combined sites 43 (40 were lung and bone, two were bone and other site, and one was lung and other site). At the time of diagnosis, 50 patients (21%) had non-radioactive iodine (RAI) avidity. Five-year disease-specific survival (DSS) was 85% and 10-year DSS was 68%, which were better than those in previous studies. After multivariate analysis, old age, male sex, metastatic site, and histologic type (follicular type) were significant factors for poor prognosis. However, negative RAI avidity status was not a significant prognostic factor after adjusting for other variables.

Conclusion

The prognosis of Korean patients with DTC and initial distant metastasis was better than in previous studies. Old age, male sex, metastasis site, and histologic type were significant prognostic factors.

Citations

Citations to this article as recorded by

Case report: A case of hyperthyroidism secondary to bone metastasis of differentiated thyroid cancer
Tingyu Gu, Zhihong Zhao, Yuanyuan Shi, Zhenhua Sun, Yao Wang, Zhiyuan He, Kun Wang
Frontiers in Oncology.2024;[Epub] CrossRef
Theranostics of Thyroid Cancer
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
Seminars in Nuclear Medicine.2024; 54(4): 470. CrossRef
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
Cancers.2023; 15(9): 2510. CrossRef
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
Petra Petranović Ovčariček, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Cancers.2023; 15(17): 4290. CrossRef
Differentiating pulmonary metastasis from benign lung nodules in thyroid cancer patients using dual-energy CT parameters
Taeho Ha, Wooil Kim, Jaehyung Cha, Young Hen Lee, Hyung Suk Seo, So Young Park, Nan Hee Kim, Sung Ho Hwang, Hwan Seok Yong, Yu-Whan Oh, Eun-Young Kang, Cherry Kim
European Radiology.2022; 32(3): 1902. CrossRef
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
Hsi-Chen Tsai, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, Miaw-Jene Liou
Diagnostics.2022; 12(1): 221. CrossRef
Long-Term Quality of Life (5-15 Years Post-Thyroidectomy) of Thyroid Carcinoma Patients in Two Tertiary Care Hospitals
Mohammed Yousef Alyousef, Mohammed Khaled Ghandour, Mohammed Al-Mohawes, Mosaad Alnwaisir, Tahera Islam, Khalid Al Qahtani
Cureus.2022;[Epub] CrossRef
Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition
Pınar Celepli, İrem Bigat, Sefika Karabulut, Salih Celepli, Sema Hücümenoğlu
Annals of Diagnostic Pathology.2022; 59: 151973. CrossRef
Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria
Yu Liang, Xingxiang Huang, Zhe Song, Yang Yang, Ju Lei, Mei Ren, Li Tan, Hui Zhang, Francis Moore
PLOS ONE.2022; 17(6): e0269994. CrossRef
Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report
Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli
World Journal of Obstetrics and Gynecology.2022; 11(3): 33. CrossRef
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Juan Antonio Vallejo Casas, Marcel Sambo, Carlos López López, Manuel Durán-Poveda, Julio Rodríguez-Villanueva García, Rita Joana Santos, Marta Llanos, Elena Navarro-González, Javier Aller, Virginia Pubul, Sonsoles Guadalix, Guillermo Crespo, Cintia Gonzál
European Thyroid Journal.2022;[Epub] CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
Evert F S van Velsen, Merel T Stegenga, Folkert J van Kemenade, Boen L R Kam, Tessa M van Ginhoven, W Edward Visser, Robin P Peeters
The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e457. CrossRef
Usefulness of a 3D‐Printed Thyroid Cancer Phantom for Clinician to Patient Communication
Dayeong Hong, Sangwook Lee, Taehun Kim, Jung Hwan Baek, Won Woong Kim, Ki‐Wook Chung, Namkug Kim, Tae‐Yon Sung
World Journal of Surgery.2020; 44(3): 788. CrossRef
Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2020; 30(3): 418. CrossRef
Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
Endocrine.2020; 70(2): 280. CrossRef
Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
PLOS ONE.2020; 15(8): e0238207. CrossRef
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Thyroid.2019; 29(12): 1804. CrossRef
Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
Xin-Yun Zhang, Jian-Wen Sun, Zhong-Ling Qiu, Yang Wang, Xiao-Yue Chen, Jin-Hua Zhao, Quan-Yong Luo
Endocrine.2019; 66(2): 254. CrossRef
Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis
Nilma Malik, Alyaksandr V. Nikitski, Elie Klam, Jason Hunt, Benjamin Witt, Barbara Chadwick, Yuri E. Nikiforov, Devaprabu Abraham
Endocrine Practice.2019; 25(12): 1255. CrossRef
Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Scientific Reports.2019;[Epub] CrossRef
Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano
Endocrine.2019; 65(3): 630. CrossRef
The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study
Young Ki Lee, Daham Kim, Dong Yeob Shin, Cho Rok Lee, Eun Jig Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Annals of Surgical Oncology.2019; 26(7): 2200. CrossRef
Risk Factors for Distant Metastasis in Follicular Thyroid Carcinoma in Korea
Shin Dol Jo, Joon-Hyop Lee, Suk Ha Kang, Yun Yeong Kim, Yong Soon Chun, Heung Kyu Park, Sang Tae Choi, Jin Mo Kang, Yoo Seung Chung
Journal of Endocrine Surgery.2019; 19(1): 1. CrossRef
Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis
Houwei Zhu, Yanqing Qu
Oncology Letters.2019;[Epub] CrossRef
甲状腺腫瘍治療の最新情報

Nippon Jibiinkoka Gakkai Kaiho.2018; 121(11): 1336. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef

Review Articles

Bone Metabolism
Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment: Hyo Min Jeong, Sun Wook Cho, Serk In Park; Endocrinol Metab. 2016;31(4):485-492. Published online December 20, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.4.485

4,442 View
48 Download
13 Web of Science
12 Crossref

Abstract PDF PubReader

The tumor microenvironment is comprised of diverse stromal cell populations in addition to tumor cells. Increasing evidence now clearly supports the role of microenvironment stromal cells in tumor progression and metastasis, yet the regulatory mechanisms and interactions among tumor and stromal cells remain to be elucidated. Bone metastasis is the major problem in many types of human malignancies including prostate, breast and lung cancers, and the biological basis of bone metastasis let alone curative approaches are largely undetermined. Among the many types of stromal cells in bone, osteoblasts are shown to be an important player. In this regard, osteoblasts are a key target cell type in the development of bone metastasis, but there are currently no drugs or therapeutic approaches are available that specifically target osteoblasts. This review paper summarizes the current knowledge on osteoblasts in the metastatic tumor microenvironment, aiming to provide clues and directions for future research endeavor.

Citations

Citations to this article as recorded by

Bone marrow adipocytes and lung cancer bone metastasis: unraveling the role of adipokines in the tumor microenvironment
Jian Li, Jialu Wu, Yanni Xie, Xijie Yu
Frontiers in Oncology.2024;[Epub] CrossRef
Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis
Min-Kyoung Song, Serk In Park, Sun Wook Cho
Journal of Bone and Mineral Metabolism.2023; 41(3): 337. CrossRef
Mobilization of monocytic myeloid-derived suppressor cells is regulated by PTH1R activation in bone marrow stromal cells
Eun Jung Lee, Kyoung Jin Lee, Seungpil Jung, Kyong Hwa Park, Serk In Park
Bone Research.2023;[Epub] CrossRef
2E‐Decene‐4,6‐diyn‐1‐ol‐acetate inhibits osteoclastogenesis through mitogen‐activated protein kinase‐c‐Fos‐NFATc1 signalling pathways
Young Ran Park, Xiang‐Dong Su, Saroj Kumar Shrestha, Seo Young Yang, Yunjo Soh
Clinical and Experimental Pharmacology and Physiology.2022; 49(3): 341. CrossRef
The let-7f-5p–Nme4 pathway mediates tumor necrosis factor α-induced impairment in osteogenesis of bone marrow-derived mesenchymal stem cells
Ying-Jie Zhao, Zheng-Chao Gao, Xi-Jing He, Jing Li
Biochemistry and Cell Biology.2021; 99(4): 488. CrossRef
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
Kyung-Hun Lee, Kyoung Jin Lee, Tae-Yong Kim, Febby Hutomo, Hyun Jin Sun, Gi Jeong Cheon, Serk In Park, Sun Wook Cho, Seock-Ah Im
Journal of Bone and Mineral Research.2020; 35(10): 1838. CrossRef
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty
Sheng Sun, Biao Xu, Qiang Zhang, Chang-song Zhao, Rui Ma, Jie He, Yao Zhang
Current HIV Research.2020; 18(4): 248. CrossRef
Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer
Wu-gui Chen, Jing Sun, Wei-wei Shen, Si-zhen Yang, Ying Zhang, Xu Hu, Hao Qiu, Shang-cheng Xu, Tong-wei Chu
Clinical & Experimental Metastasis.2019; 36(1): 39. CrossRef
Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis
Changki Lee, Young Mi Whang, Preston Campbell, Patrick L. Mulcrone, Florent Elefteriou, Sun Wook Cho, Serk In Park
Cancer Letters.2018; 414: 205. CrossRef
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg, Amber E. de Groot, Kenneth J. Pienta
Nature Reviews Clinical Oncology.2018; 15(6): 366. CrossRef
Bone Microenvironment and Role of Rank-Rankl-Opg in Breast Cancer Metastasis in Bone
Hongwei Zhang
Journal of Cancer Prevention & Current Research.2017;[Epub] CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef

Bone Metabolism
Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis: Yibin Kang; Endocrinol Metab. 2016;31(2):206-212. Published online May 13, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.206

5,584 View
55 Download
36 Web of Science
35 Crossref

Abstract PDF PubReader

Bone metastasis is a frequent occurrence in breast cancer, affecting more than 70% of late stage cancer patients with severe complications such as fracture, bone pain, and hypercalcemia. The pathogenesis of osteolytic bone metastasis depends on cross-communications between tumor cells and various stromal cells residing in the bone microenvironment. Several growth factor signaling pathways, secreted micro RNAs (miRNAs) and exosomes are functional mediators of tumor-stromal interactions in bone metastasis. We developed a functional genomic approach to systemically identified molecular pathways utilized by breast cancer cells to engage the bone stroma in order to generate osteolytic bone metastasis. We showed that elevated expression of vascular cell adhesion molecule 1 (VCAM1) in disseminated breast tumor cells mediates the recruitment of pre-osteoclasts and promotes their differentiation to mature osteoclasts during the bone metastasis formation. Transforming growth factor β (TGF-β) is released from bone matrix upon bone destruction, and signals to breast cancer to further enhance their malignancy in developing bone metastasis. We furthered identified Jagged1 as a TGF-β target genes in tumor cells that engaged bone stromal cells through the activation of Notch signaling to provide a positive feedback to promote tumor growth and to activate osteoclast differentiation. Substantially change in miRNA expression was observed in osteoclasts during their differentiation and maturation, which can be exploited as circulating biomarkers of emerging bone metastasis and therapeutic targets for the treatment of bone metastasis. Further research in this direction may lead to improved diagnosis and treatment strategies for bone metastasis.

Citations

Citations to this article as recorded by

Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Huijuan Fan, Zhanao Xu, Ke Yao, Bingxin Zheng, Yuan Zhang, Xuxiang Wang, Tengjiang Zhang, Xuan Li, Haitian Hu, Bin Yue, Zeping Hu, Hanqiu Zheng
Cancer Research.2024; 84(3): 449. CrossRef
Immune mediated support of metastasis: Implication for bone invasion
Zengfeng Xin, Luying Qin, Yang Tang, Siyu Guo, Fangfang Li, Yuan Fang, Gege Li, Yihan Yao, Binbin Zheng, Bicheng Zhang, Dang Wu, Jie Xiao, Chao Ni, Qichun Wei, Ting Zhang
Cancer Communications.2024; 44(9): 967. CrossRef
Krüppel‐like factors family in health and disease
Tingwen Xiang, Chuan Yang, Zihan Deng, Dong Sun, Fei Luo, Yueqi Chen
MedComm.2024;[Epub] CrossRef
Bone Marrow Mesenchymal Stem Cells Restrain the Migration and Invasion of Breast Cancer Cells by Up-Regulating miR-2158 and Inactivating RAI2/NLRP3 Pathway
Meiyu Xu, Shen Ye, Zhiqiang Tang, Shuai Gong
Journal of Biomaterials and Tissue Engineering.2023; 13(1): 162. CrossRef
Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer
Anita J.W.M. Brouns, Lizza E.L. Hendriks, Iris J. Robbesom-van den Berge, Annemariek J.H.M. Driessen, Guido M.J.M. Roemen, Britt L.J. van Herpen, Zoë Dekkers, Bas Heitzer, Daphne J.G. Leunissen, Laura Moonen, Ragnar Lunde, Marcel Westenend, Marjolein van
Frontiers in Oncology.2023;[Epub] CrossRef
BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion
Pengjuan Dong, Yaping Wang, Yutong Liu, Chunting Zhu, Jiaxin Lin, Ruizhe Qian, Luchun Hua, Chao Lu
Molecular Biology Reports.2022; 49(1): 373. CrossRef
Chemokines network in bone metastasis: Vital regulators of seeding and soiling
Gunjan Sharma, Ramesh Pothuraju, Ranjana Kumari Kanchan, Surinder Kumar Batra, Jawed Akhtar Siddiqui
Seminars in Cancer Biology.2022; 86: 457. CrossRef
The Signaling Pathways Associated With Breast Cancer Bone Metastasis
Xuelian Song, Changran Wei, Xiangqi Li
Frontiers in Oncology.2022;[Epub] CrossRef
Effects of 8-week noncontinuous aerobic exercise on the levels of CCL2, CCL5, and their respective receptors in female BALB/C mice suffering from breast cancer
Mehrnoosh Esmailiyan, Mehdi Kargarfard, Fahimeh Esfarjani, Golnaz Vaseghi
International Journal of Preventive Medicine.2022; 13(1): 55. CrossRef
Non‐coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance
Margherita Puppo, Hanna Taipaleenmäki, Eric Hesse, Philippe Clézardin
British Journal of Pharmacology.2021; 178(9): 1936. CrossRef
Sympathetic activity in breast cancer and metastasis: partners in crime
Francisco Conceição, Daniela M. Sousa, Joana Paredes, Meriem Lamghari
Bone Research.2021;[Epub] CrossRef
Extracellular Vesicles in Tumors: A Potential Mediator of Bone Metastasis
Shenglong Li, Wei Wang
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Bone marrow niches in the regulation of bone metastasis
Fenfang Chen, Yujiao Han, Yibin Kang
British Journal of Cancer.2021; 124(12): 1912. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
Nature Communications.2021;[Epub] CrossRef
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
Kyung-Hun Lee, Kyoung Jin Lee, Tae-Yong Kim, Febby Hutomo, Hyun Jin Sun, Gi Jeong Cheon, Serk In Park, Sun Wook Cho, Seock-Ah Im
Journal of Bone and Mineral Research.2020; 35(10): 1838. CrossRef
Polymer nanomedicines
Jindřich Kopeček, Jiyuan Yang
Advanced Drug Delivery Reviews.2020; 156: 40. CrossRef
Osteolytic metastasis in breast cancer: effective prevention strategies
Chandi C Mandal
Expert Review of Anticancer Therapy.2020; 20(9): 797. CrossRef
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
Giovanni Zarrilli, Gianluca Businello, Maria Vittoria Dieci, Silvia Paccagnella, Valentina Carraro, Rocco Cappellesso, Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Marcello Lo Mele, Matteo Fassan
International Journal of Molecular Sciences.2020; 21(21): 8102. CrossRef
Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer
Jules A Westbrook, Steven L Wood, David A Cairns, Kathryn McMahon, Renu Gahlaut, Helene Thygesen, Mike Shires, Stephanie Roberts, Helen Marshall, Maria R Oliva, Mark J Dunning, Andrew M Hanby, Peter J Selby, Valerie Speirs, Georgia Mavria, Robert E Colema
The Journal of Pathology.2019; 247(3): 381. CrossRef
The Relationship between Exosomes and Cancer: Implications for Diagnostics and Therapeutics
Wendy W. Weston, Timothy Ganey, H. Thomas Temple
BioDrugs.2019; 33(2): 137. CrossRef
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
Christopher Montemagno, Laurent Dumas, Pierre Cavaillès, Mitra Ahmadi, Sandrine Bacot, Marlène Debiossat, Audrey Soubies, Loic Djaïleb, Julien Leenhardt, Nicolas De Leiris, Maeva Dufies, Gilles Pagès, Sophie Hernot, Nick Devoogdt, Pascale Perret, Laurent
Cancers.2019; 11(7): 1039. CrossRef
Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy (Review)
Yu Zhang, Zi‑Yan Xie, Xuan‑Tong Guo, Xing‑Hua Xiao, Li‑Xia Xiong
Oncology Letters.2019;[Epub] CrossRef
NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche
Dongsheng Wang, Chenglong Zhao, Liangliang Gao, Yao Wang, Xin Gao, Liang Tang, Kun Zhang, Zhenxi Li, Jing Han, Jianru Xiao
Journal of Bone Oncology.2018; 13: 91. CrossRef
Placental exosomes: A proxy to understand pregnancy complications
Jin Jin, Ramkumar Menon
American Journal of Reproductive Immunology.2018;[Epub] CrossRef
Understanding the Bone in Cancer Metastasis
Jaime Fornetti, Alana L Welm, Sheila A Stewart
Journal of Bone and Mineral Research.2018; 33(12): 2099. CrossRef
Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis
Salvatore J. Coniglio
Frontiers in Endocrinology.2018;[Epub] CrossRef
The role of exosomes in cancer metastasis
Teresa Bernadette Steinbichler, József Dudás, Herbert Riechelmann, Ira-Ida Skvortsova
Seminars in Cancer Biology.2017; 44: 170. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Impaired Bone Matrix Alignment Induced by Breast Cancer Metastasis
Aiko Sekita, Aira Matsugaki, Takayoshi Nakano
Journal of the Japan Institute of Metals.2017; 81(6): 308. CrossRef
SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblasts
Zhan Xu, Matthew B. Greenblatt, Guang Yan, Heng Feng, Jun Sun, Sutada Lotinun, Nicholas Brady, Roland Baron, Laurie H. Glimcher, Weiguo Zou
Nature Communications.2017;[Epub] CrossRef
Bone Microenvironment and Role of Rank-Rankl-Opg in Breast Cancer Metastasis in Bone
Hongwei Zhang
Journal of Cancer Prevention & Current Research.2017;[Epub] CrossRef
Tumor–Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications
Hanqiu Zheng, Wenyang Li, Yibin Kang
Cold Spring Harbor Symposia on Quantitative Biology.2016; 81: 151. CrossRef
Breast cancer cells obtain an osteomimetic featureviaepithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction
Cong-Cong Tan, Gui-Xi Li, Li-Duan Tan, Xin Du, Xiao-Qing Li, Rui He, Qing-Shan Wang, Yu-Mei Feng
Oncotarget.2016; 7(48): 79688. CrossRef
Heterotypic models of osteosarcoma recapitulate tumor heterogeneity and biological behavior
Milcah C. Scott, Hirotaka Tomiyasu, John R. Garbe, Ingrid Cornax, Clarissa Amaya, M Gerard O'Sullivan, Subbaya Subramanian, Brad A. Bryan, Jaime F. Modiano
Disease Models & Mechanisms.2016;[Epub] CrossRef
Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment
Hyo Min Jeong, Sun Wook Cho, Serk In Park
Endocrinology and Metabolism.2016; 31(4): 485. CrossRef

Original Article

Clinical Study
Radiographic Characteristics of Adrenal Masses in Oncologic Patients: Ji Hyun Lee, Eun Ky Kim, A Ram Hong, Eun Roh, Jae Hyun Bae, Jung Hee Kim, Chan Soo Shin, Seong Yeon Kim, Sang Wan Kim; Endocrinol Metab. 2016;31(1):147-152. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.147

5,254 View
44 Download
9 Web of Science
8 Crossref

Abstract PDF PubReader

Background

We aimed to assess the usefulness of pre-contrast Hounsfield unit (HU) and mass size on computed tomography to differentiate adrenal mass found incidentally in oncologic patients.

Methods

From 2000 to 2012, 131 oncologic patients with adrenal incidentaloma were reviewed retrospectively. Receiver operating characteristic (ROC) curves were applied to determine the optimal cut-off value of the mean HU and size for detecting adrenal metastasis.

Results

The median age was 18 years, and 80 patients were male. The initial mass size was 18 mm, and 71 (54.2%) of these were on the left side. A bilateral adrenal mass was found in 11 patients (8.4%). Biochemically functional masses were observed in 9.2% of patients. Thirty-six out of 119 patients with nonfunctional masses underwent adrenalectomy, which revealed metastasis in 13. The primary cancers were lung cancer (n=4), renal cell carcinoma (n=2), lymphoma (n=2), hepatocellular carcinoma (n=2), breast cancer (n=1), and others (n=2). The area under the curve for the size and HU for clinically suspicious metastasis were 0.839 (95% confidence interval [CI], 0.761 to 0.900; P<0.001) and 0.959 (95% CI, 0.898 to 0.988; P<0.001), respectively. The cut-off value to distinguish between metastasis and benign masses were 22 mm for size and 20 for HU.

Conclusion

ROC curve results suggest that pre-contrast HU >20 can be used as a diagnostic reference to suggest metastasis in oncologic patients with adrenal masses.

Citations

Citations to this article as recorded by

Risk of malignancy in adrenal tumors in patients with a history of cancer
Radosław Samsel, Karolina Nowak, Lucyna Papierska, Edyta Karpeta, Katarzyna Roszkowska-Purska, Wacław Smiertka, Tomasz Ostrowski, Eryk Chrapowicki, Alan Grabowski, Dorota Leszczyńska, Andrzej Cichocki
Frontiers in Oncology.2023;[Epub] CrossRef
Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?
Mio Yanagisawa, Dania G. Malik, Thomas W. Loehfelm, Ghaneh Fananapazir, Michael T. Corwin, Michael J. Campbell
World Journal of Surgery.2020; 44(7): 2282. CrossRef
Predictive factors for adrenal metastasis in extra‐adrenal malignancy patients with solitary adrenal mass
Kyeong‐Hyeon Byeon, Yun‐Sok Ha, Seock‐Hwan Choi, Bum Soo Kim, Hyun Tae Kim, Eun Sang Yoo, Tae Gyun Kwon, Jun Nyung Lee, Tae‐Hwan Kim
Journal of Surgical Oncology.2018; 118(8): 1271. CrossRef
Combining Washout and Noncontrast Data From Adrenal Protocol CT
Chaan S. Ng, Emre Altinmakas, Wei Wei, Payel Ghosh, Xiao Li, Elizabeth G. Grubbs, Nancy A. Perrier, Victor G. Prieto, Jeffrey E. Lee, Brian P. Hobbs
Academic Radiology.2018; 25(7): 861. CrossRef
Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors
Youichi Ohno, Masakatsu Sone, Daisuke Taura, Toshinari Yamasaki, Katsutoshi Kojima, Kyoko Honda-Kohmo, Yorihide Fukuda, Koji Matsuo, Toshihito Fujii, Akihiro Yasoda, Osamu Ogawa, Nobuya Inagaki
Hypertension Research.2018; 41(3): 165. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
The Diverse Clinical Presentations of Adrenal Lymphoma
Awais Masood, Anna Tumyan, Daniel R. Nussenzveig, Dara N. Wakefield, Diana Barb, Hans K. Ghayee, Naim M. Maalouf
AACE Clinical Case Reports.2017; 3(4): 307. CrossRef
Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice
A Ram Hong, Jung Hee Kim, Kyeong Seon Park, Kyong Young Kim, Ji Hyun Lee, Sung Hye Kong, Seo Young Lee, Chan Soo Shin, Sang Wan Kim, Seong Yeon Kim
European Journal of Endocrinology.2017; 177(6): 475. CrossRef

Case Reports

Adrenal gland
Incidentally Detected Inoperable Malignant Pheochromocytoma with Hepatic Metastasis Treated by Transcatheter Arterial Chemoembolization: Joong Keun Kim, Bo Hyun Kim, Sung Min Baek, Dong Hun Shin, Won Jin Kim, Yun Kyoung Jeon, Sang Soo Kim, In Joo Kim; Endocrinol Metab. 2014;29(4):584-589. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.584

3,849 View
33 Download
7 Web of Science
5 Crossref

Abstract PDF PubReader

Malignant pheochromocytoma (PCC) is a rare condition. Although the liver is the second most frequent site of metastasis in malignant PCC, no definite treatments have been established. Herein, we report a case of liver metastasis of PCC that was successfully treated by transcatheter arterial chemoembolization (TACE). A 69-year-old man was admitted to the Department of Gastroenterology for evaluation of an incidental hepatic mass in August 2013. He had undergone right adrenalectomy in May 2005 and PCC had been confirmed on the basis of histopathological findings. Liver biopsy was performed, and metastatic PCC was diagnosed. The lesion appeared inoperable because of invasion of the portal vein and metastases in the lymph nodes along the hepatoduodenal ligament. Thus, TACE was performed instead. After TACE, symptoms including dizziness and cold sweating improved, and the patient's serum catecholamine levels decreased. On the basis of this case, we believe that TACE may be a useful treatment for liver metastasis in malignant PCC.

Citations

Citations to this article as recorded by

ASTAXANTHIN INHIBITS CELL PROLIFERATION, MIGRATION, INVASION AND INDUCED APOPTOSIS VIA AMPK-mTOR SIGNALING PATHWAY IN HEPATOCELLULAR CARCINOMA HEP 3B CELLS
SHUJUN LU, YAJING ZHANG, WENLI YU
Cellulose Chemistry and Technology.2023; 57(9-10): 1001. CrossRef
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome
Koshiro Nishimoto, Noriaki Lukas Santo, Masato Yonamine, Kazuhiro Takekoshi, Go Kaneko, Suguru Shirotake, Hisayo Fukushima, Yoshitaka Okada, Masanori Yasuda, Akihiro Sakurai, Masafumi Oyama, Kento Kanao
IJU Case Reports.2022; 5(6): 459. CrossRef
Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro
Jingjing Li, Weiqi Dai, Yujing Xia, Kan Chen, Sainan Li, Tong Liu, Rong Zhang, Jianrong Wang, Wenxia Lu, Yuqing Zhou, Qin Yin, Huerxidan Abudumijiti, Rongxia Chen, Yuanyuan Zheng, Fan Wang, Jie Lu, Yingqun Zhou, Chuanyong Guo
Marine Drugs.2015; 13(10): 6064. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience
Yun Mi Choi, Tae‐Yon Sung, Won Gu Kim, Jong Jin Lee, Jin‐Sook Ryu, Tae Yong Kim, Won Bae Kim, Suck Joon Hong, Dong Eun Song, Young Kee Shong
Journal of Surgical Oncology.2015; 112(8): 815. CrossRef

Thyroid
Solitary Skin Metastasis of Papillary Thyroid Carcinoma: Hyemi Kwon, Hyojung Kim, Sojung Park, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2014;29(4):579-583. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.579

4,491 View
52 Download
7 Web of Science
8 Crossref

Abstract PDF PubReader

A solitary skin metastasis is a rare manifestation of papillary thyroid carcinoma (PTC). A 55-year-old woman presented with a movable subcutaneous nodule in her anterior neck for several months. Three years ago, she underwent total thyroidectomy and remnant ablation for classical PTC (pT3N0M0) and was under thyroxine suppression therapy without any evidence of recurrent disease. The subcutaneous nodule was 0.4 cm in size, firm, and movable without any change in the overlying skin. Recurrent PTC was confirmed after excision biopsy. Eight months after, she got a new nodule along the previous excision site. After punch biopsy, metastatic PTC was confirmed in the deep dermis and was re-excised with a clear resection margin. This is the first report of a case of solitary skin metastasis of PTC in Korea. Although solitary skin metastasis of PTC is rare, it should be considered in patients with a skin nodule.

Citations

Citations to this article as recorded by

Skin Metastasis Occurring 30 Years After Thyroidectomy for Papillary Thyroid Carcinoma
Mohammed S Alwhaid, Olaa Mhish, Mutahir A Tunio, Salman AlMalki, Mushabbab Al Asiri, Khalid Al-Qahtani
Cureus.2022;[Epub] CrossRef
Solitary Nasopharyngeal Metastasis From Papillary Thyroid Carcinoma Shown on FDG PET/CT
Anqi Xu, Xiao Jie, Yan Xiu, Hongcheng Shi
Clinical Nuclear Medicine.2022; 47(5): e425. CrossRef
PD-L1-positive Anaplastic Transformation in a BRAF V600E Expressing Papillary Thyroid Carcinoma with Cutaneous Metastasis: An Unusual Case Report
Pooja Ramakant, Anand Mishra, Chanchal Rana, Kulranjan Singh
Indian Journal of Endocrine Surgery and Research.2022; 17(1): 21. CrossRef
Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review
Eleonora Farina, Fabio Monari, Giovanni Tallini, Andrea Repaci, Renzo Mazzarotto, Francesca Giunchi, Riccardo Panzacchi, Silvia Cammelli, Gilbert D. A. Padula, Francesco Deodato, Renato Pasquali, Stefano Fanti, Michelangelo Fiorentino, Alessio G. Morganti
Endocrine Pathology.2016; 27(1): 55. CrossRef
Skin manifestations of endocrine and neuroendocrine tumors
Jonathan S. Leventhal, Irwin M. Braverman
Seminars in Oncology.2016; 43(3): 335. CrossRef
Isolated Metastasis in Male Breast from Differentiated Thyroid Carcinoma – Oncological Curiosity. A Case Report and Review of Literature
Lakshminarasimman Parasuraman, Shubhada V. Kane, Prathamesh S. Pai, Kintan Shanghvi
Indian Journal of Surgical Oncology.2016; 7(1): 91. CrossRef
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinology and Metabolism.2015; 30(1): 1. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef

Thyroid
Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer: Kyung-Jin Yun, Woohyeon Kim, Eun Hee Kim, Min-Hee Kim, Dong-Jun Lim, Moo-Il Kang, Bong-Yun Cha; Endocrinol Metab. 2014;29(3):388-393. Published online September 25, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.3.388

3,923 View
32 Download
24 Web of Science
23 Crossref

Abstract PDF PubReader

Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed. Treatment with sorafenib was begun in September 2010. After 11 months treatment of sorafenib, newly developed metastatic lesions were found in mediastinal lymph nodes, liver, and bones. Considered as treatment failure, the administration of sorafenib was discontinued. Two weeks after sorafenib treatment was stopped, the disease progressed abruptly and caused death of the patient by respiratory failure. In our patient, PTC progressed rapidly after the cessation of sorafenib treatment. Patients with several other types of cancer have also experienced such rapid disease progression, termed "flare-ups." Physicians should be aware that flare-ups may occur in advanced PTC patients following the cessation of TKI therapy.

Citations

Citations to this article as recorded by

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition
Patricia O’Hare, Tabitha Cooney, Peter de Blank, David H Gutmann, Mark Kieran, Till Milde, Jason Fangusaro, Michael Fisher, Shivaram Avula, Roger Packer, Kohei Fukuoka, Kshitij Mankad, Sabine Mueller, Angela J Waanders, Enrico Opocher, Eric Bouffet, Eric
Neuro-Oncology.2024; 26(8): 1357. CrossRef
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer
Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Mario Miccoli, Maria Rosaria Galdiero, Gilda Varricchi, Rudy Foddis, Giovanni Guglielmi, Claudio Spinelli, Concettina La Motta, Salvatore Benvenga, Alessandro Ant
Expert Opinion on Investigational Drugs.2021; 30(9): 913. CrossRef
Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
He-Jiun Jiang, Yen-Hsiang Chang, Yen-Hao Chen, Che-Wei Wu, Pei-Wen Wang, Pi-Jung Hsiao
Cancer Management and Research.2021; Volume 13: 7139. CrossRef
Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
Haruhiko Yamazaki, Kiminori Sugino, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Hames, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Munetaka Masuda, Koichi Ito
Medicine.2020; 99(11): e19408. CrossRef
Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application
Rosa Maria Paragliola, Andrea Corsello, Valeria Del Gatto, Giampaolo Papi, Alfredo Pontecorvi, Salvatore Maria Corsello
Expert Opinion on Drug Discovery.2020; 15(1): 11. CrossRef
Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences
Chie Masaki, Kiminori Sugino, Naoko Saito, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito
Thyroid.2020; 30(2): 214. CrossRef
Papillary thyroid carcinoma with hyperthyroidism and multiple metastases
Li-li Zhang, Bin Liu, Fang-fang Sun, Hong-yu Li, Shuang Li, Li-rong Zhao
Medicine.2020; 99(30): e21346. CrossRef
Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma
Leszek Herbowski
Diagnostics.2020; 10(7): 457. CrossRef
Reply to “Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma”
Liviu Hitu, Calin Cainap, Dragos Apostu, Katalin Gabora, Eduard-Alexandru Bonci, Marius Badan, Alexandru Mester, Andra Piciu
Diagnostics.2020; 10(7): 458. CrossRef
Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro
Min-Hee Kim, Tae Hyeong Lee, Jin Soo Lee, Dong-Jun Lim, Peter Chang-Whan Lee
Pharmaceuticals.2020; 13(9): 208. CrossRef
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Thyroid.2019; 29(12): 1804. CrossRef
Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer
Taisuke Uchida, Hideki Yamaguchi, Kazuhiro Nagamine, Tadato Yonekawa, Eriko Nakamura, Nobuhiro Shibata, Fumiaki Kawano, Yujiro Asada, Masamitsu Nakazato
Endocrinology, Diabetes & Metabolism Case Reports.2019;[Epub] CrossRef
Thyroid Disorders in the Elderly
Kevin Higgins
Clinics in Geriatric Medicine.2018; 34(2): 259. CrossRef
Treatment of refractory thyroid cancer
Amandine Berdelou, Livia Lamartina, Michele Klain, Sophie Leboulleux, Martin Schlumberger, _ _
Endocrine-Related Cancer.2018; 25(4): R209. CrossRef
Clinical guidance for radioiodine refractory differentiated thyroid cancer
Matti L. Gild, Duncan J. Topliss, Diana Learoyd, Francis Parnis, Jeanne Tie, Brett Hughes, John P. Walsh, Donald S.A. McLeod, Roderick J. Clifton‐Bligh, Bruce G. Robinson
Clinical Endocrinology.2018; 88(4): 529. CrossRef
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients
Thomas J. Smith, Nasser Hanna, David Johnson, Sherman Baker, William A. Biermann, Julie Brahmer, Peter M. Ellis, Giuseppe Giaccone, Paul J. Hesketh, Ishmael Jaiyesimi, Natasha B. Leighl, Gregory J. Riely, Joan H. Schiller, Bryan J. Schneider, Joan Tashbar
Journal of Oncology Practice.2017; 13(12): 780. CrossRef
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports
Paul S. White, Anita Pudusseri, Stephanie L. Lee, Omar Eton
Thyroid.2017; 27(9): 1201. CrossRef
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
Fabiana Pani, Elisabetta Macerola, Fulvio Basolo, Francesco Boi, Mario Scartozzi, Stefano Mariotti
Oncology Letters.2017; 14(2): 2186. CrossRef
Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare
Terumi Tanigawa, Shintaro Morisaki, Hisanobu Fukuda, Shuichiro Yoshimura, Hisayoshi Nakajima, Kohei Kotera
Case Reports in Obstetrics and Gynecology.2017; 2017: 1. CrossRef
Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(1): 49. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography
Justine Yang Bruce, Peter Colin Scully, Lakeesha L. Carmichael, Jens C. Eickhoff, Scott B. Perlman, Jill Marie Kolesar, Jennifer L. Heideman, Robert Jeraj, Glenn Liu
Cancer Chemotherapy and Pharmacology.2015; 76(1): 187. CrossRef
Optimal Differentiated Thyroid Cancer Management in the Elderly
Donald S. A. McLeod, Kelly Carruthers, Dev A. S. Kevat
Drugs & Aging.2015; 32(4): 283. CrossRef

Solitary Pulmonary Metastasis of a Thyroid Papillary Microcarcinoma, Masquerading as Primary Lung Cancer.: Jong Hwan Lee, Se Jin Ahn, Hyung Jin Kim, Sang Eon Jang, Jae Soo Koh, Yun Yong Lee, Cheol Hyeon Kim, Jae Cheol Lee; Endocrinol Metab. 2011;26(1):78-83. Published online March 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.1.78

2,257 View
23 Download
1 Crossref

Abstract PDF

Although pulmonary metastasis of thyroid cancer is not uncommon, it mostly occurs as multiple discrete nodules on the lung parenchyma. Because thyroid cancer presenting with an isolated large lung mass is extremely rare and the diagnosis is frequently based on small pieces of tissue obtained by a fine needle, the wrong diagnosis such as lung cancer is prone to be made. A 60-year-old man was admitted for evaluation of a lung mass detected on chest radiography. Cytological examination of the bronchial washing specimens suggested adenocarcinoma. Surgery for early lung cancer was performed considering that no other abnormalities were found during the work-up that included 18-fludeoxyglucose positron emission tomography computer tomography (18FDG-PET/CT). Unexpectedly, the diagnosis of papillary thyroid cancer with lung metastasis was made, which prompted us to evaluate the thyroid gland and then remove the primary cancer by subsequent operation. Although it is uncommon, physician should be aware of this possibility, which could help to avoid the wrong diagnosis. Here we report on a typical case of solitary pulmonary metastasis of thyroid cancer and we summarize the previously reported cases with a review of the relevant literature.

Citations

Citations to this article as recorded by

Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative 131I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports
Chan-Hee Jung, Hyeon-Jeong Goong, Bo-Yeon Kim, Jung-Mi Park, Jeong-Ja Kwak, Chul-Hee Kim, Hyun-Sook Hong, Sung-Koo Kang, Ji-Oh Mok
Journal of Medical Case Reports.2012;[Epub] CrossRef

First
Prev
Page of 3
Next
Last

Search